GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ipca Laboratories Ltd (NSE:IPCALAB) » Definitions » EV-to-EBIT

Ipca Laboratories (NSE:IPCALAB) EV-to-EBIT : 33.55 (As of May. 11, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Ipca Laboratories EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Ipca Laboratories's Enterprise Value is ₹343,009 Mil. Ipca Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₹10,224 Mil. Therefore, Ipca Laboratories's EV-to-EBIT for today is 33.55.

The historical rank and industry rank for Ipca Laboratories's EV-to-EBIT or its related term are showing as below:

NSE:IPCALAB' s EV-to-EBIT Range Over the Past 10 Years
Min: 14.84   Med: 22.81   Max: 115.34
Current: 33.54

During the past 13 years, the highest EV-to-EBIT of Ipca Laboratories was 115.34. The lowest was 14.84. And the median was 22.81.

NSE:IPCALAB's EV-to-EBIT is ranked worse than
75.64% of 669 companies
in the Drug Manufacturers industry
Industry Median: 17.95 vs NSE:IPCALAB: 33.54

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Ipca Laboratories's Enterprise Value for the quarter that ended in Dec. 2023 was ₹282,411 Mil. Ipca Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was ₹10,224 Mil. Ipca Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 3.62%.


Ipca Laboratories EV-to-EBIT Historical Data

The historical data trend for Ipca Laboratories's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ipca Laboratories EV-to-EBIT Chart

Ipca Laboratories Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.18 23.37 16.93 23.14 25.22

Ipca Laboratories Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 26.23 25.22 22.31 29.57 27.63

Competitive Comparison of Ipca Laboratories's EV-to-EBIT

For the Drug Manufacturers - Specialty & Generic subindustry, Ipca Laboratories's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ipca Laboratories's EV-to-EBIT Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ipca Laboratories's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Ipca Laboratories's EV-to-EBIT falls into.



Ipca Laboratories EV-to-EBIT Calculation

Ipca Laboratories's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=343008.780/10224.1
=33.55

Ipca Laboratories's current Enterprise Value is ₹343,009 Mil.
Ipca Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹10,224 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ipca Laboratories  (NSE:IPCALAB) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Ipca Laboratories's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 ) =EBIT / Enterprise Value (Q: Dec. 2023 )
=10224.1/282410.6076
=3.62 %

Ipca Laboratories's Enterprise Value for the quarter that ended in Dec. 2023 was ₹282,411 Mil.
Ipca Laboratories's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹10,224 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ipca Laboratories EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Ipca Laboratories's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Ipca Laboratories (NSE:IPCALAB) Business Description

Traded in Other Exchanges
Address
125, Kandivli Industrial Estate, Kandivli (West), Mumbai, MH, IND, 400067
Ipca Laboratories Ltd is a specialty and generic drug manufacturing company. The company's principal activity is Development, Manufacturing and Marketing of Pharmaceuticals Products. The company operates multiple subsidiaries with revenue generation split roughly between India and the rest of the world. Ipca's products are exported to more than 100 countries across the globe. Ipca has only one reportable primary business segment, pharmaceuticals.

Ipca Laboratories (NSE:IPCALAB) Headlines

No Headlines